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2017 University Grant Program, Seed Grant Final Report 
Alyson J. Smith, Ph.D. 
The purpose of this UGP proposal was to obtain preliminary data to elucidate the ability of different TLR 
agonists, alone and in combination with one another and chemotherapy, to induce regression of solid tumors. 
The specific objectives of this proposal were to: 1) evaluate the ability of a TLR7/8 and/or TLR4 agonist, 
individually and in combination with one another and the chemotherapy cyclophosphamide, to induce growth 
arrest or remission of tumors and 2) to dissect the underlying mechanism of action of these compounds on the 
immune system and in the tumor microenvironment (TME). In support of these aims two in vivo studies of similar 
structure were done (Figure 1). 
 In the initial study two 
escalating doses of the TLR4 
agonist CRX-527 and the 
TLR7/8 agonist CRX-727 were 
assessed alone and in 
combination with one another 
and/or the chemotherapy 
cyclophosphamide (cytoxan). 
Mice bearing CT-26 colon 
tumors on their flanks were 
treated 3x 1/week. Toxicity in the combination groups after the first administration necessitated 2-fold decrease 
in compound concentration upon reinjection (i.e. from 50/10 µg at week 1 to 25/5 µg at weeks 2 and 3). All 
groups without the inclusion of the chemotherapy reached high tumor burden quickly, though addition of CRX-
527 did appear to slow the 
growth of tumors (Figure 2, 
upper). Cyclophosphamide on 
its own was able to diminish 
tumors but upon cessation of 
treatment, tumors began to 
rapidly regrow (Figure 2, lower 
left, red line). Addition of higher 
dose CRX-527 or the 
combination of CRX-527/CRX-
727 to the chemo, induced 
immunological memory 
responses capable of 
maintaining low tumor levels 
(green, light red or yellow lines). 
While CRX-527 synergized with 
chemotherapy to decrease 
tumor burden, the greatest 
effect on tumor decrease was 
the addition of both TLR4 and TLR7/8 agonists (Figure 2, lower right, yellow and light red). 
 A follow up study was done with a lower dose of cytoxan and compounds to assess if greater synergy 
would be seen at lower dose. Interestingly, decreasing the chemotherapy does by two-fold did not greatly 
diminish the tumor ablation ability as was expected. With this lower chemotherapy dose though it was again 
seen that tumor clearance by chemo was a transient phenotype that rebounded upon cessation of treatment 
(Figure 3, lower left, red line). Interestingly, in this study the lower doses of the TLR4 agonist appear to be less 
efficacious, while the TLR7/8 agonist (CRX-727) was actually more efficacious (Figure 3, lower right). With 
either 5 or 1 µg CRX-527 there was no synergistic benefit to chemotherapy-induced tumor burden reduction or 
induction of immunological memory (i.e. tumors again rebounded in size after treatment). However, with the 
lowest dose of CRX-727 (1 µg) there was the greatest synergy and immunological memory when combined 
with chemotherapy (Figure 3, lower figures). This interesting phenotype of increased activity of the TLR7/8 
agonist alone at lower doses suggests a clear dose-dependent activity of all of these compounds. Whereby 
titrating one or both is necessary to maximize response. In addition to assessing the TLR4 and TLR7/8 
 
Figure 2. Colon tumor growth in response to treatment regimens. 
 
 
Figure 1. Outline of solid tumor murine studies. 
 
2 
 
compounds in this study a novel 
compound was also included – 
UM-1024, a purported Mincle 
agonist. Mincle is a disparate 
innate receptor thought to be 
responsible for driving a Th17 
response. While the role of 
Th17 effort cells in cancer 
therapy is not clearly elucidated 
and often conflicting, we chose 
to include this molecule to being 
to elucidate this further. 
Interestingly while the 
compound on its own had no 
effect at tumor reduction, 
combination with the 
chemotherapy was synergistic. 
50% of the mice were cured of 
the tumor when given this 
combination regimen (Figure 3, 
lower right). Though not as efficacious as low dose TLR7/8 this compound presents an intruding path of study 
and should be investigated more thoroughly.   
 In addition, in this study spleens were harvested from mice upon sacrifice (either because to tumor 
burden or study end) and evaluated for immunophenotyping. Analysis of this data is complicated as different 
groups were harvested/stained/analyzed at different times based on tumor burden and it appears there were 
differences in staining across these groups making cross group comparison inaccurate. However, when the 
median tumor volume of the end groups (those that made it to day 49 of the study, i.e. those with CTX) was 
plotted against the percentage of several 
different immune cell subtypes, some 
correlations were garnered. Unexpectedly no 
correlation between the percentage of M1 
macrophages or Treg cells and tumor burden 
were found (Figure 4A and E). Negative 
correlation (i.e. more tumor was seen with less 
cells) was seen for M MDSC, CD8 and CD4 T 
cells (Figure 4D, F and G), while the increased 
presence of M2 or PMN MDSC was positively 
correlated (i.e. more tumor with more cells) 
(Figure 4B and C). This data would suggest 
that to drive successful tumor clearance 
suppression the PMN myeloid derived 
suppressor and the M2 macrophage subsets 
must be diminished with augmentation of CD4 
and CD8 T cell subsets.  
 
Extramural Grant Submissions 
In continuation of this work, and fulfilment of 
UGP requirements, a U01 entitled ‘Investigation 
of combinatorial innate immunotherapy with 
chemotherapy to enhance responses in colon 
cancer’ was submitted to the National Cancer 
Institute in Jan of 2018 (application identifier 
238684). Review is expected in late May 2018.  
 
 
Figure 3. Colon tumor growth in response to treatment regimens. 
 
 
 
 
Figure 4. Correlation between final median tumor volume and 
percent immune cell subtypes.  
 
